Menu
Recruiting NCT06591936

Genetic Profile of Alpha Thalassemia Children at Sohag University Hospital .

Observational Alpha-Thalassemia

For patients and families

In plain language

Fill the application

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: Alpha-Thalassemia. Basic parameters: 0 Days — 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Egypt
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

Genetic profile of alpha thalassemia children at sohag university hospital ,the aim to determine the prevelance , molecular character of the disorder, characterized by decreased synthesis of alpha -globin Recent work to provide mechanisms for phenotypic heterogeneity .

Primary outcome measures

  • PCR for prevelance of mutation phenotype [Time frame: one year]

Eligibility criteria

Inclusion criteria

  • Acase suspecteed of alpha thalassemia
  • age between 0-18years
  • micocytic hypochromic anemia not iron deficiency anemia or Beta thalassemia

Exclusion criteria

  • Age more than 18 years
  • healthy children free from any chronic hematological disease
  • micocytic hypochromic anemia either iron deficiency anemia or Beta thalassemia

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

Egypt · 1 center
  • Sohag University Hospital — Sohag

Identifiers

NCT: NCT06591936 · soh-med-24-08-02MS

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗